Smith & Nephew plc (LON:SN)‘s stock had its “buy” rating reiterated by stock analysts at Deutsche Bank AG in a research report issued on Friday, October 13th.

A number of other equities research analysts also recently commented on the stock. Credit Suisse Group reissued a “neutral” rating and issued a GBX 1,280 ($16.89) price objective on shares of Smith & Nephew plc in a research report on Friday, July 28th. Citigroup Inc. reissued a “sell” rating and issued a GBX 1,160 ($15.31) price objective on shares of Smith & Nephew plc in a research report on Monday, July 10th. Berenberg Bank reissued a “hold” rating and issued a GBX 1,300 ($17.15) price objective on shares of Smith & Nephew plc in a research report on Tuesday, July 18th. Jefferies Group LLC reissued a “buy” rating and issued a GBX 1,515 ($19.99) price objective on shares of Smith & Nephew plc in a research report on Thursday, October 12th. Finally, HSBC Holdings plc reissued a “hold” rating and issued a GBX 1,320 ($17.42) price objective on shares of Smith & Nephew plc in a research report on Monday, July 10th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and two have assigned a buy rating to the company’s stock. Smith & Nephew plc has a consensus rating of “Hold” and a consensus target price of GBX 1,300.58 ($17.16).

TRADEMARK VIOLATION WARNING: “Smith & Nephew plc’s (SN) “Buy” Rating Reaffirmed at Deutsche Bank AG” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/13/deutsche-bank-ag-reaffirms-buy-rating-for-smith-nephew-plc-sn.html.

In other Smith & Nephew plc news, insider Virginia Bottomley purchased 223 shares of the firm’s stock in a transaction that occurred on Wednesday, August 16th. The stock was purchased at an average price of GBX 1,380 ($18.21) per share, for a total transaction of £3,077.40 ($4,060.97).

Smith & Nephew plc Company Profile

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.

Analyst Recommendations for Smith & Nephew plc (LON:SN)

Receive News & Ratings for Smith & Nephew plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew plc and related companies with MarketBeat.com's FREE daily email newsletter.